Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation

Matilde B Ørum; Frederikke F Rönsholt; Majbritt Jeppesen; Elisabeth Bendstrup; Terese L Katzenstein; Peter Ott; Michael Perch; Tacjana Pressler; Tavs Qvist; Søren Jensen-Fangel

doi:10.1002/ppul.26217

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation

Matilde B Ørum^*, Frederikke F Rönsholt, Majbritt Jeppesen, Elisabeth Bendstrup, Terese L Katzenstein, Peter Ott, Michael Perch, Tacjana Pressler, Tavs Qvist, Søren Jensen-Fangel

^*Corresponding author for this work

4 Citations (Scopus)

Abstract

We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

Original language	English
Journal	Pediatric Pulmonology
Volume	58
Issue number	2
Pages (from-to)	602-605
Number of pages	4
ISSN	8755-6863
DOIs	https://doi.org/10.1002/ppul.26217
Publication status	Published - Feb 2023

Keywords

CFTR therapy
cystic fibrosis
cystic fibrosis transmembrane conductance regulator therapy
ETI
solid organ transplantation
Double-Blind Method
Humans
Organ Transplantation
Aminophenols
Cystic Fibrosis Transmembrane Conductance Regulator/genetics
Benzodioxoles/adverse effects
Cystic Fibrosis/drug therapy
Chloride Channel Agonists
Retrospective Studies
Mutation
Drug Combinations

Access to Document

10.1002/ppul.26217

Cite this

@article{d8d166155b18486597c969ee11f6b4b8,

title = "Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation",

abstract = "We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.",

keywords = "CFTR therapy, cystic fibrosis, cystic fibrosis transmembrane conductance regulator therapy, ETI, solid organ transplantation, Double-Blind Method, Humans, Organ Transplantation, Aminophenols, Cystic Fibrosis Transmembrane Conductance Regulator/genetics, Benzodioxoles/adverse effects, Cystic Fibrosis/drug therapy, Chloride Channel Agonists, Retrospective Studies, Mutation, Drug Combinations",

author = "{\O}rum, {Matilde B} and R{\"o}nsholt, {Frederikke F} and Majbritt Jeppesen and Elisabeth Bendstrup and Katzenstein, {Terese L} and Peter Ott and Michael Perch and Tacjana Pressler and Tavs Qvist and S{\o}ren Jensen-Fangel",

year = "2023",

month = feb,

doi = "10.1002/ppul.26217",

language = "English",

volume = "58",

pages = "602--605",

journal = "Pediatric Pulmonology",

issn = "8755-6863",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation

AU - Ørum, Matilde B

AU - Rönsholt, Frederikke F

AU - Jeppesen, Majbritt

AU - Bendstrup, Elisabeth

AU - Katzenstein, Terese L

AU - Ott, Peter

AU - Perch, Michael

AU - Pressler, Tacjana

AU - Qvist, Tavs

AU - Jensen-Fangel, Søren

PY - 2023/2

Y1 - 2023/2

N2 - We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

AB - We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

KW - CFTR therapy

KW - cystic fibrosis

KW - cystic fibrosis transmembrane conductance regulator therapy

KW - ETI

KW - solid organ transplantation

KW - Double-Blind Method

KW - Humans

KW - Organ Transplantation

KW - Aminophenols

KW - Cystic Fibrosis Transmembrane Conductance Regulator/genetics

KW - Benzodioxoles/adverse effects

KW - Cystic Fibrosis/drug therapy

KW - Chloride Channel Agonists

KW - Retrospective Studies

KW - Mutation

KW - Drug Combinations

UR - http://www.scopus.com/inward/record.url?scp=85141966470&partnerID=8YFLogxK

U2 - 10.1002/ppul.26217

DO - 10.1002/ppul.26217

M3 - Journal article

C2 - 36314653

VL - 58

SP - 602

EP - 605

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 2

ER -

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this